Medikamentöse Therapie des kolorektalen Karzinoms – Palliative Chemotherapie – Palliativmedizin

Das kolorektale Karzinom liegt mit einer Inzidenz von etwa 70 000 Neuerkrankungen in Deutschland mit an der Spitze aller Tumorerkrankungen; die Heilungsraten über alle Patienten bzw. Stadien ist mit etwa 55  % nach wie vor schlecht. Durch optimierte Therapiealgorithmen, neue Zytostatika/molekular gezielte Therapien und molekulare Prädiktoren des Therapieerfolges sowie enge interdisziplinäre Zusammenarbeit darf man in den kommenden Jahren auf eine Verbesserung der Prognose hoffen.

The colorectal carcinoma is among the most frequently occurring carcinomas in Germany with an incidence of about 70000 new cases and the rate of cured cases of patients or stages continues to be as low as 55 per cent. We may hope that the prognostic rate will improve due to improved therapy algorithms, new therapies with cystomolecular targeting and molecular predictors.

Colorectal cancer - liver metastases - guidelines - palliative therapy

Literatur

• 1 Amado R, Wolf M, Peeters M.. Wild–Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.  J Clin Oncol. 2008;  26 1626-1634
• 2 Schmiegel W. et al. . S3–Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008. Ergebnis einer evidenzbasierten Konsensuskonferenz (8.–9. Juni 2007). Update S3–Guideline „Colorectal Cancer” 2008.  Z Gastr. 2008;  46 799-840
• 3 Nordlinger B. et al. . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable livermetastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.  Lancet. 2008;  371 1007-1016
• 4 Falcone A. et al. . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first–line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.  J Clin Oncol. 2007;  25 1670-1676
• 5 Van Cutsem E, Nowacki M, Lang I.. Randomized phase III study of irinotecan and 5–FU/FA with or without cetuximab in the first–line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25
• 6 Van Cutsem E, Lang I, D'haens G. et al. . KRAS status and efficacy in the first–line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2008;  26
• 7 Grünberger B. et al. . Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with potentially resectable metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1830-1850
• 8 Cassidy J. et al. . Surgery with curative intent in patients (pts) treated with first–line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2008;  26
• 9 Saltz LB. et al. . Bevacizumab in combination with oxaliplatin–based chemotherapy as first–line therapy in metastatic colorectal cancer: a randomized phase III study.  J Clin Oncol. 2008;  26 2013-2019
• 10 Folprecht G. et al. . Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.  Ann Oncol. 2005;  16 1311-1319
• 11 Aloia T. et al. . Liver histology and surgical outcome after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.  J Clin Oncol. 2006;  24 4983-4990
• 12 Grothey A. et al. . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment.  J Clin Oncol. 2004;  22 1209-1214
• 13 Scheithauer W. et al. . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.  BMJ. 1993;  306 752-755
• 14 Cunningham D. et al. . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.  Lancet. 1998;  352 1413-1418
• 15 Jonker DJ, Karapetis CS, O'Callaghan J. et al. . Cetuximab for the Treatment of Colorectal Cancer.  N Engl J Med. 2007;  357 2040-2048
• 16 Van Cutsem E. et al. . Open–label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy–refractory metastatic colorectal cancer.  J Clin Oncol. 2007;  25 1658-1664
• 17 Earle. et al. . Aggressiveness of cancer care near the end of life: is it a quality–of–care issue?.  J Clin Oncol. 2008;  26 3860-3866

Korrespondenz